Success Metrics

Active Trials
4(100%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Recruiting3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

active_not_recruiting125%
recruiting375%

Recent Activity

4 active trials
Showing 4 of 4
recruitingphase_2

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420
recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170
recruitingphase_3

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT07091630
active_not_recruitingphase_2

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

NCT06284954

Clinical Trials (4)

Showing 4 of 4 trials
NCT07284420Phase 2

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Recruiting
NCT07294170

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Recruiting
NCT07091630Phase 3

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Recruiting
NCT06284954Phase 2

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4